Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.

Journal of clinical laboratory analysis - 1 Oct 2023

Wanas Hanaa, Kamel Mai Hamed, William Emad Adel, Fayad Tarek, Abdelfattah Mohamed Essmat, Elbadawy Hossein Mostafa, Mikhael Emily Samir

Abstract excerpt

BACKGROUND: Tacrolimus (TAC) is the mainstay of immunosuppressive regimen for kidney transplantations. Its clinical use is complex due to high inter-individual variations which can be partially attributed to genetic variations at the metabolizing enzymes CYP3A4 and CYP3A5. Two single nucleotide polymorphisms (SNPs), CYP3A4*22 and CYP3A5*3, have been reported as important causes of differences in pharmacokinetics...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Egypt

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Kidney

Share to Kidney Transplantation

Share to Living Donors

Share to Polymorphism, Single Nucleotide

Share to Tacrolimus

Source

Open in PubMed Open full text

Identifiers

PMID: 37789683
DOI: 10.1002/jcla.24969
PMCID: PMC10681408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of CYP3A4 and CYP3A5 genetic variations on tacrolimus treatment of living-donor Egyptian kidney transplanted patients.PMID 37789683Read ↗

Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.Semantic proximity Read ↗

CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted PatientsSemantic proximity Read ↗

The pharmacogenetics of Tacrolimus in Algerian kidney recipients' patients.Semantic proximity Read ↗

Combined Role of CYP3A4 and CYP3A5 genetic variants in tacrolimus dose-adjusted trough levels: a clinical retrospective study in kidney transplant patients.Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant CenterSemantic proximity Read ↗

CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.Semantic proximity Read ↗

Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patientsSemantic proximity Read ↗

Genotype-guided tacrolimus dosing: The role of CYP3A5 polymorphisms in optimising kidney transplant immunosuppression in BhutanSemantic proximity Read ↗

Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.Semantic proximity Read ↗

Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.